Skip to main content
. 2015 Nov 10;5(3):e1100791. doi: 10.1080/2162402X.2015.1100791

Figure 5.

Figure 5.

Modulation of IL-17A and IL-21 production by CD4+ CD45RAneg T cells detected in periphery during breast tumor progression. The capacity of CD4+ CD45RAneg T cells to produce IL-17A or IL-21 was assessed in WB after short-term polyclonal stimulation (P/I) in presence of brefeldin A on cohorts of patients with breast cancers at different stage of disease (PT (n = 46), FR (n = 34), SR (n = 20)) and compared to a HD cohort (n = 31) Results are presented as percentage of CD4+ CD45RAneg T cells producing IL-17A (A) or IL-21 (B) or co-producing IL-21 and TNFα, IL-21 and IFNγ or IL-21 and IL-2 (C). * p value< 0.05, **: p value < 0.01.